Sinphar Pharmaceutical Co. Ltd. · TWSE:1734
Sinphar Pharmaceutical — 2020 Sinphar Pharmaceutical Investor Conference
27 slides from Sinphar Pharmaceutical's conference presentation, Dec 29, 2020
Slide 1: Sinphar Pharmaceutical Co., Ltd. Investor Conference
SINPHAR (1734:TT) SynCore Bio (4192:TT) SINPHAR PHARMACEUTICAL CO.,LTD Investor Conference 2020/12/29 1
Slide 2: Disclaimer
免責聲明 本簡報是建立於本公司從各項來源所取得之資 訊。有些資訊可能受未來不確定性因素影響， 致使與原先本公司對於未來前景的說明迥異。 未來若有變更或調整時，請以公開資訊觀測站 公告資訊為依據。 This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cau
Slide 3: Index
Index 1. Instruction 2. Important Events 3. Group Operation 4. 2020Q3 Financial Report 5. Social Responsibility 3
Slide 4: Founded in Taiwan, Step Forward to The World
Founded in Taiwan, Step Forward to The World 1977 2002 2012 Established Sinphar Invested Sinphar TianLi, He-Tian Tianli Merged ZuniMed Biotech Ilan, Taiwan Hangzhou (CN)、Xinjiang(CN) Nantou,TW Generic、functional food、 Generic、TCM、Natural Resources Medical facilities cosmetic 1997 2008 Established Ca
Slide 5: Group's Great Health Map
Group’s Great Health Map Multi-strength of Generic Drugs The R&D power of New Drug Strategic plan of Natural Herbal Resources 5
Slide 6: Full age and all-round protection
Full age and all-round protection Vision care Brain care Heart care Dermatology Ophthalmology Pediatrics Immune Gastrointestinal Oncology Otolaryngology Orthopedics Bone health care regulation care Allergy Obstetrics & Beauty care Delay aging General Surgery Plastic Surgery regulation Gynecology Chr
Slide 7: Sinphar Health Hall
Sinphar Health Hall Share relevant medical and health knowledge with the public ： • The Facebook fan page has nearly a hundred professional shares that convey the right medicine and food knowledge. • About 12,000 people have visited the plant in 2020 to know about the manufacturing process of pharma
Slide 8: Intelligent Plant
SAP PSI management Intelligent Plant MES Manufacturing execution control WMS Warehouse and inventory management ASPROVA Creates intelligent production schedules Inbound ISO/IEC 27001 record Information 進貨 Purchase IQC 入庫 Inbound Security SA SAP Management System, ISMS Picking RFID pick
Slide 9: Information Security Management System, ISMS
Information Security Management System, ISMS ISO 27001 specification System usage Compliance with permissions international standards Information usage Compliance with permissions external audit requirements Risk control Security awareness Invest resources to protect enterprise resource management s
Slide 10: Quality System
Quality System 1. We have obtained PIC/S license extension (PMDA cancer factory) at Nov. 12, 2020 by TFDA approval. 2. During COVID-19 epidemic, Sinphar has RT-PCR machine and was been invited to join the epidemic prevention team by the Ministry of Health and Welfare (MOHW). 3. For the purpose of go
Slide 11: Energy Saving and Carbon Reduction
Energy Saving and Carbon Reduction 1. In 2016, the street light and electric light in the factory are changed from traditional lamps to LED lamps. Which can save 1% of electricity consumption every year. 2. In 2017, the air conditioning system phased in physical solution dehumidification equipment.
Slide 12: Growth
Growth Therapeutic drug • New products are expected to launch in 2021 for 4 items. • Co-develop and manufacture with Japanese pharmaceutical companies and attack the ASEAN market. Functional Supplements • New products are expected to launch in 2021 for 7 items. • Agent Japanese products into the dom
Slide 13: International Market
International Market Japan: Product G has been launched in 2020. Looking forward to continuous growth. Thailand : Product T has been submitted on Oct. 2020. Expected to be launch in 2021. Product G has been submitted on July 2020. Expected to get certificate in 2021. Product A has been BE assessment
Slide 14: COVID-19 Response
COVID-19 Response Emergency response: • Sinphar Group and inter-departmental sharing of epidemic prevention information and communication platform. • Promulgate and rehearse the phased contingency implementation plan for factories, offices and new work codes. • Provide employee with anti-epidemic ap
Slide 15: Group resources integration
Group resources integration Sinphar & SynCore Drugs in R & D cooperation and Sinphar & TianLi Oncology manufacturing improve. R&D achievement mutually benefit. Dosages Patents cooperation layout. Natural Medical Herbal Facilities Resources Sinphar & ZuniMed ISO15378 Class 100,000 15 clean room.
Slide 16: Pipeline of New Products
Pipeline of New Products UNMET MEDICAL NEED UNMET MEDICAL NEED 16
Slide 17: Development of New Drug
Development of New Drug Market value From Market Research Engine, the global market value of Pancreatic Cancer will increase to US$13 billion in 2021. According to GLOBOCAN,Pancreatic cancer mortality rate is almost equal to incidence, which is expected to increase by 40% by 2030. Market Research En
Slide 18: Target field of Natural Resources
Target field of Natural Resources Lipucan® Protygold ® Memoregain® TLCT Plus 天力速康® 杏补宜 ® 天力再生® (Poria cocos triterpenoids) (Walnut oligopeptide) (Cistanche tubulosa extracts) Sleep quality Sports Nutrition Boost Respiratory Health Proven by healthy study (3 multinational patents) (4 multinational pa
Slide 19: Strengths and strategies
Strengths and strategies • In 2020, the main business market of Sinphar Tianli’s food Ingredients is in the China. Market • Food market demand trends in 2020: upregulate immune function, improve sleep quality, ant fatigue, help improve memory, gut health, sports nutrition, and beauty. • Existing pro
Slide 20: Recent group revenue
NTD in Thousand Recent group revenue 1,900,000 1,850,000 1,800,000 1,750,000 1,700,000 1,650,000 1,600,000 1,550,000 1,500,000 2018Q1-Q3 2019Q1-Q3 2020Q1-Q3 Term 2018 Q1-Q3 2019 Q1-Q3 2020 Q1-Q3 2018全年度 2019全年度 Therapeutic 1,112,925 1,180,870 1,243,483 1,528,051 1,651,348 drug Functional 449,686 470
Slide 21: Profit and Loss
NTD in Thousand Profit and Loss Period 2020 Q1~Q3 2019 Q1~Q3 2019 Revenue 1,847,962 1,723,050 2,394,589 Gross Profit 38% 38% 39% S&M 239,222 240,151 324,733 G&A 160,773 182,781 234,056 R&D 344,107 377,543 527,805 Profit before Tax -33,298 -105,734 -86,706 Net income (loss) attributable to parent com
Slide 22: Cash flows
NTD in Thousand Cash flows Sinphar Syncore 2020 Q1~Q3 2020 Q1~Q3 Net Cash generated by 82,520 -245,618 operating activities Net Cash used in investing -110,995 -1,445 activities Net Cash generated by 276,953 478,113 financing activities Cash and cash equivalents, 1,087,002 617,413 end of the period
Slide 23: Ratio
Ratio 2020Q3 2019Q3 Current ratio(%) 187.73 171.84 Cumulative revenue growth(%) 7.25 6.53 Operating expense ratio(%) 40.16 46.68 Employment costs (%) 27.09 29.02 Account receivable turnover 4.31 4.12 Account payable turnover 7.00 6.77 Inventory turnover 2.45 2.76 Fixed property and equipment turnove
Slide 24: 2020 Events
2020 Events 1. Innovative research and development of "anti-fatigue unique formula" won the United States invention patent certification, and has been the national anti-fatigue health food certification. 2. Research and development and production ｢娘家好茯敏膠囊｣ won the Taiwan Health Food Society awarded
Slide 25: Corporate Social Responsibility
Corporate Social Responsibility Promote social care, medical prevention and health education • Host health forum, biotechnology camp. Combined medical, academia, and biotechnology community to set up an interaction platform. Also, cultivate talented personnel. • Continually to sponsor Breast Cancer
Slide 26: Corporate Social Responsibility
Corporate Social Responsibility Support sports and educational activities in long term • Provide internship for students from Kaohsiung Medical University, Taipei Medical University, National Defense Medical Center, China Medical University and Chia Nan University of Pharmacy & Science. Also provide
Slide 27: Q&A
Q&A • Cooperation & Development: 張智超。 (886-2-27603688 # 2304) • Investor Services: 陳淑夏。 (886-2-27603688 # 2237) 27
Sinphar Pharmaceutical — 2020 Sinphar Pharmaceutical Investor Conference on 6ix